GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Capex-to-Operating-Cash-Flow

DarioHealth (DarioHealth) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

DarioHealth's Capital Expenditure for the three months ended in Dec. 2023 was $-0.08 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-7.34 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


DarioHealth Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for DarioHealth's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth Capex-to-Operating-Cash-Flow Chart

DarioHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DarioHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of DarioHealth's Capex-to-Operating-Cash-Flow

For the Health Information Services subindustry, DarioHealth's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DarioHealth's Capex-to-Operating-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where DarioHealth's Capex-to-Operating-Cash-Flow falls into.



DarioHealth Capex-to-Operating-Cash-Flow Calculation

DarioHealth's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.584) / -30.379
=N/A

DarioHealth's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.083) / -7.341
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DarioHealth  (NAS:DRIO) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


DarioHealth Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of DarioHealth's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


DarioHealth (DarioHealth) Business Description

Traded in Other Exchanges
N/A
Address
18 W. 18th Street, New York, NY, USA, 10011
DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.
Executives
Jon H. Kaplan director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael director, officer: Chief Executive Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher officer: Chief Operating Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen officer: GM MSK 8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis director 8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked director 8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer director 8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson officer: President, GM of North America C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi director C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david officer: Chief Financial Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller director 8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry officer: See Remarks 15 ROCKRIDGE RD, LARCHMONT NY 10538-3918